piracetam has been researched along with Convulsive Generalized Seizure Disorder in 57 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 7.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| " MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA)." | 7.76 | Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats. ( Arcieri, S; Coppola, G; D'Aniello, A; Messana, T; Pascotto, A; Signoriello, G; Verrotti, A, 2010) |
| "Lately, few case reports have brought forth limited cases of levetiracetam (LEV)-induced thrombocytopenia." | 7.76 | Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. ( Goyal, MK; Sahaya, K; Sarwal, A; Singh, NN, 2010) |
| "12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital." | 7.74 | Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ( Bailey, KS; Barone, G; Boothe, DM; Dewey, CW; Kortz, GD, 2008) |
| "A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy." | 7.74 | [Clinical experience with levetiracetam for adults with epilepsy]. ( Barcs, G; Szucs, A, 2007) |
| "In this open-label add-on study of levetiracetam in refractory childhood epilepsy syndromes, we studied the effect of a rapid introduction of levetiracetam on the total seizure frequency in 21 children, known to have partial and generalized seizures." | 7.72 | Effect of levetiracetam in refractory childhood epilepsy syndromes. ( Buyse, G; Ceulemans, B; Deconinck, A; Lagae, L, 2003) |
| "Levetiracetam-treated cats had higher freedom from myoclonic seizures (50." | 5.46 | Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study. ( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017) |
| "Lennox-Gastaut syndrome is an epileptic encephalopathy characterized by multiple seizure types, mental retardation, and a slow spike-and-wave pattern on electroencephalography." | 5.32 | Levetiracetam in the treatment of Lennox-Gastaut syndrome. ( De Los Reyes, EC; Hale, SE; Sharp, GB; Williams, JP, 2004) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 3.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| " MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA)." | 3.76 | Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats. ( Arcieri, S; Coppola, G; D'Aniello, A; Messana, T; Pascotto, A; Signoriello, G; Verrotti, A, 2010) |
| "Lately, few case reports have brought forth limited cases of levetiracetam (LEV)-induced thrombocytopenia." | 3.76 | Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. ( Goyal, MK; Sahaya, K; Sarwal, A; Singh, NN, 2010) |
| "A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy." | 3.74 | [Clinical experience with levetiracetam for adults with epilepsy]. ( Barcs, G; Szucs, A, 2007) |
| "12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital." | 3.74 | Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ( Bailey, KS; Barone, G; Boothe, DM; Dewey, CW; Kortz, GD, 2008) |
| "In this open-label add-on study of levetiracetam in refractory childhood epilepsy syndromes, we studied the effect of a rapid introduction of levetiracetam on the total seizure frequency in 21 children, known to have partial and generalized seizures." | 3.72 | Effect of levetiracetam in refractory childhood epilepsy syndromes. ( Buyse, G; Ceulemans, B; Deconinck, A; Lagae, L, 2003) |
| "Levetiracetam was well tolerated with 1." | 2.73 | Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. ( Berkovic, SF; Falter, U; Knowlton, RC; Leroy, RF; Schiemann, J, 2007) |
| "7% after 26 weeks on a median levetiracetam dosage of 22 mg/kg/day." | 2.73 | Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. ( Arts, WF; Augustijn, P; Brouwer, OF; Callenbach, PM; Geerts, AT; Geerts, Y; Gunning, WB; Peeters, EA; Stroink, H; ten Houten, R; Weber, AM, 2008) |
| "Levetiracetam-treated patients were more likely to respond to treatment than patients receiving placebo (OR = 4." | 2.73 | Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. ( Andermann, E; Andermann, F; Gough, WB; Meyvisch, P; Noachtar, S; Schiemann-Delgado, J, 2008) |
| "Of 21 patients, 16 had partial and five generalized epilepsy." | 2.72 | Use of levetiracetam in treating epilepsy associated with other medical conditions. ( Di Bonaventura, C; Egeo, G; Fattouch, J; Giallonardo, AT; Manfredi, M; Mari, F; Prencipe, M; Vaudano, AE, 2006) |
| "Levetiracetam was generally well tolerated although 11/25 (44%) of patients reported some tiredness, weight change or rash." | 2.71 | Levetiracetam as add-on therapy in generalised epilepsies. ( Kumar, SP; Smith, PE, 2004) |
| "Levetiracetam (LEV) has proven effective for partial seizures, suggesting the need to trial it in generalised epilepsy." | 2.71 | A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. ( Beran, RG; Weber, S, 2004) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Occurrence of generalized tonic-clonic seizures (GTCS) is one of the most important risk factors of seizure-related complications and comorbidities in patients with epilepsy." | 2.50 | Pharmacotherapy for tonic-clonic seizures. ( Rheims, S; Ryvlin, P, 2014) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Levetiracetam-treated cats had higher freedom from myoclonic seizures (50." | 1.46 | Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study. ( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017) |
| "Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles." | 1.43 | A New SV2A Ligand for Epilepsy. ( Rogawski, MA, 2016) |
| "Levetiracetam has been authorized for use in Israel as an add-on therapy for intractable epilepsy since May 2006." | 1.39 | Levetiracetam in children, adolescents and young adults with intractable epilepsy: efficacy, tolerability and effect on electroencephalogram--a pilot study. ( Eidlitz-Markus, T; Feldman, L; Goldberg-Stern, H; Kramer, U; Perez, S; Phatal-Valevski, A; Pollak, L, 2013) |
| " Levetiracetam monotherapy at a dosage of 40 mg/kg/day improved the clinical findings, and seizures were controlled at the end of the first month of treatment." | 1.38 | Acquired epileptiform opercular syndrome: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings and efficacy of levetiracetam therapy. ( Akın, R; Arslan, M; Ince, S; Ünay, B; Vurucu, S; Yiş, U, 2012) |
| "Idiopathic generalized epilepsy (IGE) was diagnosed in 85 cases, cryptogenic focal epilepsy in 107 cases, symptomatic focal epilepsy in 51 cases, unclassified epilepsy in 32 cases." | 1.38 | [Idiopathic generalized epilepsy in young women: choise of treatment strategy]. ( Kotov, AS, 2012) |
| "Epilepsy was most common among those with maternal deletions and unknown subtypes, with catastrophic epilepsies present in only these two subtypes." | 1.35 | Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. ( Braun, EK; Bruno, P; Conant, KD; Nespeca, MP; Said, RR; Thibert, RL; Thiele, EA, 2009) |
| "Levetiracetam was discontinued in seven patients overall." | 1.34 | Levetiracetam monotherapy in children with epilepsy. ( Khurana, DS; Kothare, SV; Legido, A; Melvin, JJ; Valencia, I, 2007) |
| "This prospective open-label study used flexible dosing schedules of levetiracetam (LEV) in patients with refractory epilepsy attending a single centre to explore its effectiveness in everyday clinical practice." | 1.33 | Levetiracetam in refractory epilepsy: a prospective observational study. ( Brodie, MJ; Mohanraj, R; Parker, PG; Stephen, LJ, 2005) |
| "We examined the efficacy, optimum dosage and adverse effects of levetiracetam in two prospective trials in children with epilepsy." | 1.33 | Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. ( Buyse, G; Ceulemans, B; Lagae, L, 2005) |
| "We have treated a patient with juvenile myoclonic epilepsy who had frequent and inconvenient morning myoclonus with 3,200 mg of piracetam daily." | 1.33 | Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy. ( Andermann, E; Andermann, F; Khani, YA, 2005) |
| "Seizures are similar to those of reading epilepsy (RE)." | 1.33 | Language-induced epilepsy, acquired stuttering, and idiopathic generalized epilepsy: phenotypic study of one family. ( Carré, S; Hirsch, E; Rudolf, G; Szepetowski, P; Thibault, A; Valenti, MP; Vrielynck, P, 2006) |
| "Levetiracetam (LEV) is a new antiepileptic drug highly effective as add-on treatment in refractory partial epilepsies." | 1.33 | Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. ( Rocamora, R; Schulze-Bonhage, A; Wagner, K, 2006) |
| "Lennox-Gastaut syndrome is an epileptic encephalopathy characterized by multiple seizure types, mental retardation, and a slow spike-and-wave pattern on electroencephalography." | 1.32 | Levetiracetam in the treatment of Lennox-Gastaut syndrome. ( De Los Reyes, EC; Hale, SE; Sharp, GB; Williams, JP, 2004) |
| " A dose-response relationship was also explored." | 1.31 | Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? ( Somerville, ER, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 37 (64.91) | 29.6817 |
| 2010's | 18 (31.58) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Ballvé, A | 1 |
| Salas-Puig, J | 1 |
| Quintana, M | 1 |
| Campos, D | 1 |
| Llauradó, A | 1 |
| Raspall, M | 1 |
| Fonseca, E | 1 |
| Abraira, L | 1 |
| Santamarina, E | 1 |
| Toledo, M | 1 |
| Coppola, G | 2 |
| Piccorossi, A | 1 |
| Operto, FF | 1 |
| Verrotti, A | 2 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Marson, AG | 3 |
| Rheims, S | 1 |
| Ryvlin, P | 1 |
| El-Farahaty, RM | 1 |
| El-Mitwalli, A | 1 |
| Azzam, H | 1 |
| Wasel, Y | 1 |
| Elrakhawy, MM | 1 |
| Hasaneen, BM | 1 |
| Mundlamuri, RC | 1 |
| Sinha, S | 1 |
| Subbakrishna, DK | 1 |
| Prathyusha, PV | 1 |
| Nagappa, M | 1 |
| Bindu, PS | 1 |
| Taly, AB | 1 |
| Umamaheswara Rao, GS | 1 |
| Satishchandra, P | 1 |
| Lowrie, M | 1 |
| Thomson, S | 1 |
| Bessant, C | 1 |
| Sparkes, A | 1 |
| Harvey, RJ | 1 |
| Garosi, L | 1 |
| Rogawski, MA | 1 |
| Rosenfeld, WE | 1 |
| Benbadis, S | 1 |
| Edrich, P | 1 |
| Tassinari, CA | 1 |
| Hirsch, E | 2 |
| Thibert, RL | 1 |
| Conant, KD | 1 |
| Braun, EK | 1 |
| Bruno, P | 1 |
| Said, RR | 1 |
| Nespeca, MP | 1 |
| Thiele, EA | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 5 |
| Arcieri, S | 1 |
| D'Aniello, A | 1 |
| Messana, T | 1 |
| Signoriello, G | 1 |
| Pascotto, A | 1 |
| Sahaya, K | 1 |
| Goyal, MK | 1 |
| Sarwal, A | 1 |
| Singh, NN | 1 |
| Trinka, E | 1 |
| Van Paesschen, W | 1 |
| Kälviäinen, R | 1 |
| Marovac, J | 1 |
| Duncan, B | 1 |
| Buyle, S | 1 |
| Hallström, Y | 1 |
| Hon, P | 1 |
| Muscas, GC | 1 |
| Newton, M | 1 |
| Meencke, HJ | 1 |
| Smith, PE | 2 |
| Pohlmann-Eden, B | 1 |
| Arslan, M | 1 |
| Yiş, U | 1 |
| Vurucu, S | 1 |
| Ince, S | 1 |
| Ünay, B | 1 |
| Akın, R | 1 |
| Karlov, VA | 2 |
| Freĭdkova, NV | 1 |
| Rusanova, LV | 1 |
| Kotov, AS | 1 |
| Sönnichsen, AC | 1 |
| Goldberg-Stern, H | 1 |
| Feldman, L | 1 |
| Eidlitz-Markus, T | 1 |
| Kramer, U | 1 |
| Perez, S | 1 |
| Pollak, L | 1 |
| Phatal-Valevski, A | 1 |
| Geisler, F | 1 |
| Smyth, M | 1 |
| Oechtering, J | 1 |
| Tuetuencue, S | 1 |
| Klostermann, F | 1 |
| Nolte, CH | 1 |
| Mawhinney, E | 1 |
| Craig, J | 1 |
| Morrow, J | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Liggan, B | 1 |
| Irwin, B | 1 |
| Delanty, N | 2 |
| Hunt, SJ | 1 |
| Cohen, J | 1 |
| Lagae, L | 2 |
| Buyse, G | 2 |
| Deconinck, A | 1 |
| Ceulemans, B | 2 |
| Krauss, GL | 1 |
| Betts, T | 1 |
| Gergey, G | 1 |
| Yarrow, H | 1 |
| Miller, A | 1 |
| Leppik, IE | 1 |
| Biton, V | 1 |
| Sander, JW | 1 |
| Wieser, HG | 1 |
| Gallagher, MJ | 1 |
| Eisenman, LN | 1 |
| Brown, KM | 1 |
| Erbayat-Altay, E | 1 |
| Hecimovic, H | 1 |
| Fessler, AJ | 1 |
| Attarian, HP | 1 |
| Gilliam, FG | 1 |
| De Los Reyes, EC | 1 |
| Sharp, GB | 1 |
| Williams, JP | 1 |
| Hale, SE | 1 |
| French, JA | 3 |
| Kanner, AM | 3 |
| Bautista, J | 3 |
| Browne, T | 3 |
| Harden, CL | 3 |
| Theodore, WH | 3 |
| Bazil, C | 3 |
| Stern, J | 3 |
| Schachter, SC | 3 |
| Bergen, D | 3 |
| Hirtz, D | 3 |
| Montouris, GD | 3 |
| Nespeca, M | 3 |
| Gidal, B | 3 |
| Marks, WJ | 3 |
| Turk, WR | 3 |
| Fischer, JH | 3 |
| Bourgeois, B | 3 |
| Wilner, A | 3 |
| Faught, RE | 3 |
| Sachdeo, RC | 3 |
| Beydoun, A | 3 |
| Glauser, TA | 3 |
| Brodtkorb, E | 1 |
| Klees, TM | 1 |
| Nakken, KO | 1 |
| Lossius, R | 1 |
| Johannessen, SI | 1 |
| Kumar, SP | 1 |
| Weber, S | 1 |
| Beran, RG | 1 |
| Mohanraj, R | 1 |
| Parker, PG | 1 |
| Stephen, LJ | 1 |
| Brodie, MJ | 1 |
| Khani, YA | 1 |
| Andermann, F | 2 |
| Andermann, E | 2 |
| Chappell, B | 1 |
| Crawford, P | 1 |
| Vlasov, PN | 1 |
| Ji-qun, C | 1 |
| Ishihara, K | 1 |
| Nagayama, T | 1 |
| Serikawa, T | 1 |
| Sasa, M | 1 |
| Mandelbaum, DE | 2 |
| Bunch, M | 2 |
| Kugler, SL | 2 |
| Venkatasubramanian, A | 2 |
| Wollack, JB | 2 |
| Panayiotopoulos, CP | 1 |
| Grünewald, R | 1 |
| Di Bonaventura, C | 1 |
| Mari, F | 1 |
| Fattouch, J | 1 |
| Egeo, G | 1 |
| Vaudano, AE | 1 |
| Manfredi, M | 1 |
| Prencipe, M | 1 |
| Giallonardo, AT | 1 |
| Labate, A | 1 |
| Colosimo, E | 1 |
| Gambardella, A | 1 |
| Leggio, U | 1 |
| Ambrosio, R | 1 |
| Quattrone, A | 1 |
| Valenti, MP | 1 |
| Rudolf, G | 1 |
| Carré, S | 1 |
| Vrielynck, P | 1 |
| Thibault, A | 1 |
| Szepetowski, P | 1 |
| Kinirons, P | 1 |
| McCarthy, M | 1 |
| Doherty, CP | 1 |
| Rocamora, R | 1 |
| Wagner, K | 1 |
| Schulze-Bonhage, A | 1 |
| Barcs, G | 1 |
| Szucs, A | 1 |
| Khurana, DS | 1 |
| Kothare, SV | 1 |
| Valencia, I | 1 |
| Melvin, JJ | 1 |
| Legido, A | 1 |
| Berkovic, SF | 1 |
| Knowlton, RC | 1 |
| Leroy, RF | 1 |
| Schiemann, J | 1 |
| Falter, U | 1 |
| Callenbach, PM | 1 |
| Arts, WF | 1 |
| ten Houten, R | 1 |
| Augustijn, P | 1 |
| Gunning, WB | 1 |
| Peeters, EA | 1 |
| Weber, AM | 1 |
| Stroink, H | 1 |
| Geerts, Y | 1 |
| Geerts, AT | 1 |
| Brouwer, OF | 1 |
| Noachtar, S | 1 |
| Meyvisch, P | 1 |
| Gough, WB | 1 |
| Schiemann-Delgado, J | 1 |
| Bailey, KS | 1 |
| Dewey, CW | 1 |
| Boothe, DM | 1 |
| Barone, G | 1 |
| Kortz, GD | 1 |
| Löscher, W | 1 |
| Hönack, D | 1 |
| Somerville, ER | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Year[NCT00150774] | Phase 3 | 116 participants | Interventional | 2001-11-30 | Completed | ||
| A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Ped[NCT00160550] | Phase 3 | 154 participants | Interventional | 2001-09-30 | Completed | ||
| A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/[NCT00175903] | Phase 3 | 1,701 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Cognitive Effects of Treatment of Interictal Discharges[NCT00916149] | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives[NCT00266149] | Phase 3 | 10 participants | Interventional | 2003-06-30 | Terminated | ||
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Effects of Levetiracetam on Cortical Excitability in Humans[NCT00006191] | 14 participants | Observational | 2000-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | IEDs/hour (Mean) |
|---|---|
| No Treatment | -28.8 |
| Levetiracetam | .54 |
Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | -1.27 |
| Levetiracetam | 1 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .36 |
| Levetiracetam | .33 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .45 |
| Levetiracetam | .33 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.09 |
| Levetiracetam | .17 |
Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .02 |
| Levetiracetam | .1 |
Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 34.96 |
| Levetiracetam | .45 |
Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | -0.01 |
| Levetiracetam | .01 |
Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 1.04 |
| Levetiracetam | -11.33 |
Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.55 |
| Levetiracetam | 2.67 |
Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.27 |
| Levetiracetam | -0.4 |
Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 8.09 |
| Levetiracetam | 5.5 |
Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 2.45 |
| Levetiracetam | 2.5 |
Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 2.8 |
| Levetiracetam | .83 |
Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .73 |
| Levetiracetam | -.33 |
Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 3.2 |
| Levetiracetam | 1.5 |
Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .01 |
| Levetiracetam | .03 |
Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -66.76 |
| Levetiracetam | .61 |
Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -4.73 |
| Levetiracetam | -4.36 |
Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | .18 |
| Levetiracetam | -0.5 |
Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 0.18 |
| Levetiracetam | 1.5 |
Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | -.01 |
| Levetiracetam | 0 |
Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -31.99 |
| Levetiracetam | -25.54 |
Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Levetiracetam | 19.6 |
Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards. (NCT00916149)
Timeframe: 1 and 11 Weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .36 |
| Levetiracetam | -1.67 |
Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | .98 |
| Levetiracetam | -7.3 |
Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -9.51 |
| Levetiracetam | 11.29 |
Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | -1.55 |
| Levetiracetam | -.83 |
Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .02 |
| Levetiracetam | .14 |
Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 2.98 |
| Levetiracetam | -6.1 |
Change in Verbal Working Memory Accuracy Score (range 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | 0 |
| Levetiracetam | -.02 |
Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -54.76 |
| Levetiracetam | -9.36 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
9 reviews available for piracetam and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Anticonvulsant drugs for generalized tonic-clonic epilepsy.
Topics: Acetamides; Anticonvulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Female; Fructose; Humans | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Pharmacotherapy for tonic-clonic seizures.
Topics: Acetamides; Anticonvulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Fructose; Humans; Lacosa | 2014 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combina | 2003 |
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Antipsychotic Agents; Carbamazepine; Child; Clinic | 2004 |
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Tr | 2004 |
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epile
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Cyclohexan | 2004 |
11 trials available for piracetam and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2015 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blin | 2009 |
KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2013 |
Levetiracetam as add-on therapy in generalised epilepsies.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalized; Female; | 2004 |
A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Generalized; Female; Follow-Up Studies; Humans; Levetiracetam; Mal | 2004 |
[Efficacy of keppra in combined therapy in pharmacoresistant adult epilepsy patients].
Topics: Adult; Anticonvulsants; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Ep | 2005 |
Use of levetiracetam in treating epilepsy associated with other medical conditions.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsies, Partial; Epilepsy, | 2006 |
Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsies, | 2006 |
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Epilepsy, Ge | 2007 |
Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Topics: Adolescent; Anticonvulsants; Child; Disorders of Excessive Somnolence; Dose-Response Relationship, D | 2008 |
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chi-Square Distribution; Child; Double-Blind Method; Epile | 2008 |
37 other studies available for piracetam and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Levetiracetam as first-line monotherapy for Idiopathic Generalized Epilepsy in women.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy, Generalized; Female; Follow-Up Studies; Humans; Leveti | 2021 |
Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carotid Arteries; Carotid Intima-Media Thickness; Cross- | 2015 |
Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Epilepsies, Myoclonic; Epilepsy, Generalized; Female; | 2017 |
A New SV2A Ligand for Epilepsy.
Topics: Animals; Anticonvulsants; Binding Sites; Epilepsies, Partial; Epilepsy, Generalized; Humans; Levetir | 2016 |
Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options.
Topics: Adolescent; Adult; Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Clonazepam; Comorbid | 2009 |
Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats.
Topics: Animals; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Electroshock; Epilepsy, Gen | 2010 |
Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Blood Platelets; Drug Therapy, Combinat | 2010 |
Acquired epileptiform opercular syndrome: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings and efficacy of levetiracetam therapy.
Topics: Anticonvulsants; Child, Preschool; Deglutition Disorders; Dysarthria; Electroencephalography; Epilep | 2012 |
[Complex therapy of idiopathic forms of epilepsy with small doses of valproates and levetiracetam].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy, Absence; | 2012 |
[Idiopathic generalized epilepsy in young women: choise of treatment strategy].
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsy, Generalized; Fe | 2012 |
The problem of non-superiority: what do we know after KOMET?
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy, Generalized; Female; Humans; Levetira | 2013 |
Levetiracetam in children, adolescents and young adults with intractable epilepsy: efficacy, tolerability and effect on electroencephalogram--a pilot study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsies, Par | 2013 |
Auto-antibody-negative limbic-like encephalitis as the first manifestation of Neurosyphilis.
Topics: Aged; Alcoholism; Anticonvulsants; Autoantibodies; Cognition Disorders; Epilepsy, Generalized; Human | 2013 |
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalize | 2013 |
Levetiracetam monotherapy for primary generalised epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy, Generalized; Humans; | 2003 |
Effect of levetiracetam in refractory childhood epilepsy syndromes.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Epilepsies, Part | 2003 |
Levetiracetam treatment of idiopathic generalised epilepsy.
Topics: Adolescent; Adult; Aged; Epilepsy, Generalized; Female; Humans; Levetiracetam; Male; Middle Aged; Pi | 2003 |
Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy.
Topics: Action Potentials; Electroencephalography; Epilepsy, Generalized; Humans; Levetiracetam; Monitoring, | 2004 |
Levetiracetam in the treatment of Lennox-Gastaut syndrome.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy, Generaliz | 2004 |
Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Resistance; Drug Th | 2004 |
Levetiracetam in refractory epilepsy: a prospective observational study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Resistance; Drug Therapy, Combination; Electroencepha | 2005 |
Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Dr | 2005 |
Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy.
Topics: Comorbidity; Epilepsy, Generalized; Female; Follow-Up Studies; Humans; Middle Aged; Myoclonic Epilep | 2005 |
An audit of lamotrigine, levetiracetam and topiramate usage for epilepsy in a district general hospital.
Topics: Adult; Aged; Anticonvulsants; Cohort Studies; Drug Utilization; Epilepsy; Epilepsy, Generalized; Fem | 2005 |
Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Dose-Response R | 2005 |
Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Dose-Response Relationship, | 2005 |
Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Dose-Response Relationship, | 2005 |
Idiopathic generalized epilepsies: a review and modern approach.
Topics: Anticonvulsants; Brain; Child; Diagnosis, Differential; Electroencephalography; Epilepsy, Generalize | 2005 |
Levetiracetam in the treatment of idiopathic generalized epilepsies.
Topics: Adult; Animals; Anticonvulsants; Child; Disease Models, Animal; Epilepsy, Generalized; Female; Human | 2005 |
Language-induced epilepsy, acquired stuttering, and idiopathic generalized epilepsy: phenotypic study of one family.
Topics: Adolescent; Age of Onset; Anticonvulsants; Comorbidity; Electroencephalography; Electromyography; Ep | 2006 |
Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
Topics: Anticonvulsants; Drug Resistance; Drug Therapy, Combination; Epilepsies, Partial; Epilepsy, Generali | 2006 |
Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epilepsy, Gen | 2006 |
[Clinical experience with levetiracetam for adults with epilepsy].
Topics: Adult; Aged; Anticonvulsants; Drug Resistance; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; | 2007 |
Levetiracetam monotherapy in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsies, Partial; Epilepsy, Generalized; Fe | 2007 |
Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Drug Therapy, Combination; Epilepsies, Partial; Epilep | 2008 |
Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Dose-Response Relationship, Drug; Electrodes; | 1993 |
Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy, Generalized; Fructose; Humans; Levetiracetam; Nipeco | 2002 |